- Home
- INTS vs SUGP Comparison
INTS vs SUGP Comparison
Compare INTS & SUGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- SUGP
- Stock Information
- Founded
- INTS 2012
- SUGP 1998
- Country
- INTS United States
- SUGP Hong Kong
- Employees
- INTS 16
- SUGP N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- SUGP
- Sector
- INTS Health Care
- SUGP
- Exchange
- INTS Nasdaq
- SUGP NYSE
- Market Cap
- INTS 30.8M
- SUGP N/A
- IPO Year
- INTS 2023
- SUGP 2024
- Fundamental
- Price
- INTS $2.06
- SUGP $0.76
- Analyst Decision
- INTS Strong Buy
- SUGP
- Analyst Count
- INTS 3
- SUGP 0
- Target Price
- INTS $8.50
- SUGP N/A
- AVG Volume (30 Days)
- INTS 38.4K
- SUGP 25.5K
- Earning Date
- INTS 03-13-2025
- SUGP 04-08-2025
- Dividend Yield
- INTS N/A
- SUGP N/A
- EPS Growth
- INTS N/A
- SUGP 1.19
- EPS
- INTS N/A
- SUGP 0.11
- Revenue
- INTS N/A
- SUGP $23,446,259.00
- Revenue This Year
- INTS N/A
- SUGP N/A
- Revenue Next Year
- INTS N/A
- SUGP N/A
- P/E Ratio
- INTS N/A
- SUGP $8.03
- Revenue Growth
- INTS N/A
- SUGP 11.29
- 52 Week Low
- INTS $1.50
- SUGP $0.55
- 52 Week High
- INTS $5.28
- SUGP $3.29
- Technical
- Relative Strength Index (RSI)
- INTS 46.37
- SUGP 43.81
- Support Level
- INTS $1.88
- SUGP $0.79
- Resistance Level
- INTS $2.18
- SUGP $1.00
- Average True Range (ATR)
- INTS 0.21
- SUGP 0.06
- MACD
- INTS -0.01
- SUGP 0.01
- Stochastic Oscillator
- INTS 39.73
- SUGP 21.46
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.